Teva Pharmaceutical Industries Ltd. (TEVA) Given a $72.00 Price Target at Maxim Group
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been given a $72.00 price objective by stock analysts at Maxim Group in a research note issued on Friday. The brokerage presently has a a “buy” rating on the stock. Maxim Group’s price objective would suggest a potential upside of 67.60% from the stock’s current price.
TEVA has been the subject of several other reports. Jefferies Group cut their target price on shares of Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating for the company in a research note on Thursday, July 14th. RBC Capital Markets set a $71.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Sunday, September 11th. Mizuho reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, July 25th. Bank of America Corp. set a $72.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Saturday, October 1st. Finally, Leerink Swann restated an “outperform” rating and issued a $66.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $66.94.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) traded down 2.40% during trading on Friday, reaching $41.93. 6,457,979 shares of the company traded hands. The firm’s 50 day moving average is $48.87 and its 200-day moving average is $52.17. Teva Pharmaceutical Industries has a 12-month low of $41.90 and a 12-month high of $66.55. The stock has a market capitalization of $38.32 billion, a P/E ratio of 28.01 and a beta of 0.74.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/teva-pharmaceutical-industries-ltd-teva-receives-buy-rating-from-maxim-group.html
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Thursday, August 4th. The company reported $1.25 EPS for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.05. Teva Pharmaceutical Industries had a net margin of 7.56% and a return on equity of 17.77%. The business earned $5 billion during the quarter, compared to analysts’ expectations of $4.86 billion. During the same period in the prior year, the company earned $1.43 earnings per share. The firm’s revenue was up 1.4% on a year-over-year basis. On average, equities research analysts anticipate that Teva Pharmaceutical Industries will post $5.24 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. PGGM Investments raised its stake in Teva Pharmaceutical Industries by 64.7% in the second quarter. PGGM Investments now owns 1,344,928 shares of the company’s stock worth $67,556,000 after buying an additional 528,470 shares during the last quarter. Psagot Investment House Ltd. raised its stake in Teva Pharmaceutical Industries by 81.9% in the second quarter. Psagot Investment House Ltd. now owns 1,070,005 shares of the company’s stock worth $53,746,000 after buying an additional 481,820 shares during the last quarter. Deprince Race & Zollo Inc. raised its stake in Teva Pharmaceutical Industries by 614.8% in the second quarter. Deprince Race & Zollo Inc. now owns 566,084 shares of the company’s stock worth $28,434,000 after buying an additional 486,894 shares during the last quarter. RNC Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 384.5% in the second quarter. RNC Capital Management LLC now owns 392,970 shares of the company’s stock worth $19,739,000 after buying an additional 311,856 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its stake in Teva Pharmaceutical Industries by 216.5% in the first quarter. Panagora Asset Management Inc. now owns 702,480 shares of the company’s stock worth $37,590,000 after buying an additional 480,509 shares during the last quarter. 63.36% of the stock is owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.